Business
Bluejay Diagnostics Provides First Quarter 2026 Corporate Update
ACTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes in critical care settings, today provided a corporate update highlighting progress achieved during the first quarter of 2026 and recent operational developments related to its Symphony™ near-patient diagnostic platform. During the first quarter of 2026, Bluejay continued advancing the clinical, manufacturing, and regulatory act
About this update from Bluejay Diagnostics, Inc.
[{"type":"image","alt":"Bluejay Diagnostics, Inc.","displaySize":"","headline":null,"caption":"Bluejay Diagnostics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/97303deb2c9a2ba3f4da1f553026db16"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Auycbcl9a3832uA47b54Tw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTYy/https://media.zenfs.com/en/globenewswire.com/97303deb2c9a2ba3f4da1f553026db16","width":150,"height":44},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/Auycbcl9a3832uA47b54Tw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTYy/https://media.zenfs.com/en/globenewswire.com/97303deb2c9a2ba3f4da1f553026db16","width":150,"height":44}},"lazy":false},{"type":"text","content":"ACTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes in critical care settings, today provided a corporate update highlighting progress achieved during the first quarter of 2026 and recent operational developments related to its Symphony™ near-patient diagnostic platform.","length":390,"tagName":"p"},{"type":"text","content":"During the first quarter of 2026, Bluejay continued advancing the clinical, manufacturing, and regulatory activities supporting the development of its Symphony IL-6 test for sepsis patient monitoring and risk assessment in critical care settings.","length":246,"tagName":"p"},{"type":"text","content":"Q1 2026 and Recent Highlights","length":29,"tagName":"p"},{"type":"text","content":"• Continued enrollment progress in the ongoing SYMON-II pivotal clinical study evaluating the role of IL-6 in sepsis and septic shock patients. As of May 5, 2026, approximately 680 patients have been enrolled toward the target enrollment of 750 patients across participating clinical sites.","length":290,"tagName":"p"},{"type":"text","content":"• Advanced manufacturing readiness activities for Symphony cartridges in collaboration with Sanyoseiko Co. Ltd., Bluejay’s contract manufacturing organization. The Company successfully resolved technical issues related to the Symphony cartridge manufacturing process and is progressing toward analytical and clinical validation activities intended to support future regulatory submission.","length":388,"tagName":"p"},{"type":"text","content":"...